Program
HRS-3738
A development code.
In Jiangsu HengRui Medicine's pipeline, CRBN-E3
. Its studies are mostly in Lymphoma, Non-Hodgkin, led by Jiangsu HengRui Medicine.
Furthest: phase 1, since Apr 25, 20221 company-led study, 1 open or runningNext primary completion: Dec 30, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 11 open or running | phase 1since Apr 25, 2022 | Apr 25, 2022 | Dec 30, 2026phase 1 · NCT05363800 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-3738
, phase 1, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 25, 2022First study: phase 1 study in RecurrenceFirst studyNCT05363800 · 74 enrolled · China
Ahead
- Dec 30, 2026Primary completion: phase 1 study in RecurrenceNCT05363800
TargetBeta
“CRBN-E3”the company's pipeline, read by Claude · source
Other programs on CRBN
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lenalidomiderule | Bristol-Myers Squibb | phase 4 | 109 |
| pomalidomiderule | Bristol-Myers Squibb | phase 4 | 51 |
| mezigdomide | Bristol-Myers Squibb | phase 3 | 12 |
| golcadomide | Bristol-Myers Squibb | phase 3 | 11 |
| Cereblon E3 Ubiquitin Ligase Modulating Drug BMS-986506 | Bristol-Myers Squibb | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05363800Recurrence · China | 1 | Active, not recruiting | Dec 30, 2026 | 74 |
How it is read
Names in the registry
- “HRS-3738”, 1 entry
Codes read as this program: HRS3738.
Conditions, from the studies’ own filings
- Lymphoma, Non-Hodgkin, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.